Physician profile
Nasm A Sheikh
NPI 1609802644
$1,362.41
in general payments reported to CMS, 2019-2025
16 companies · $94.49 in 2025
The $94.49 reported for 2025 was less than what a typical Allergy & Immunology (Internal Medicine) provider received nationally (typical 2025 total: $681).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $360 · 2021: $310 · 2022: $145 · 2023: $13.29 · 2024: $166 · 2025: $94.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $156 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $155.73 |
| Education | $118.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $340.47 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $326.87 | 2019-2024 | Airsupra, Breztri |
| Biohaven Pharmaceuticals, INC. | $120.32 | 2021 | |
| Glaxosmithkline, LLC. | $114.83 | 2019-2024 | Trelegy Ellipta |
| Genzyme Corporation | $78.08 | 2019-2021 | |
| Allergan, INC. | $71.69 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.12 | 2019-2021 | |
| Abbvie INC. | $48.77 | 2021-2022 | |
| Optinose US, INC. | $43.89 | 2019-2020 | |
| Amgen INC. | $39.45 | 2020-2021 | |
| Mylan Specialty L.P. | $28.65 | 2020 | |
| Aimmune Therapeutics, INC. | $24.93 | 2021 | |
| Alk-Abello, INC | $24.88 | 2019 | |
| Galderma Laboratories, L.P. | $20.99 | 2025 | Nemluvio |
| Sunovion Pharmaceuticals INC. | $16.36 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biocryst US Sales Co., LLC | $13.11 | 2024 | Orladeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nasm Sheikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.